These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 21487020

  • 1. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH, Hung MC.
    J Biol Chem; 2011 Jun 10; 286(23):20558-68. PubMed ID: 21487020
    [Abstract] [Full Text] [Related]

  • 2. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
    Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, Chang KY, Chang WC, Chou TC, Chou CK, Tsai CH, Hung MC.
    PLoS One; 2011 Jun 10; 6(6):e21428. PubMed ID: 21731744
    [Abstract] [Full Text] [Related]

  • 3. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
    Lemos C, Kathmann I, Giovannetti E, Calhau C, Jansen G, Peters GJ.
    Br J Cancer; 2009 Apr 07; 100(7):1120-7. PubMed ID: 19277036
    [Abstract] [Full Text] [Related]

  • 4. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 5. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC.
    Int J Oncol; 2006 Nov 15; 29(5):1237-46. PubMed ID: 17016657
    [Abstract] [Full Text] [Related]

  • 6. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
    Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B.
    Biochem Pharmacol; 2012 Aug 01; 84(3):260-7. PubMed ID: 22548830
    [Abstract] [Full Text] [Related]

  • 7. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
    Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS.
    Oncol Rep; 2009 Feb 01; 21(2):483-9. PubMed ID: 19148526
    [Abstract] [Full Text] [Related]

  • 8. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
    Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ.
    Curr Drug Targets; 2014 Feb 01; 15(14):1322-30. PubMed ID: 25479544
    [Abstract] [Full Text] [Related]

  • 9. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD.
    Cancer Biol Ther; 2007 Mar 01; 6(3):432-8. PubMed ID: 17312388
    [Abstract] [Full Text] [Related]

  • 10. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL.
    J Cell Physiol; 2011 Sep 01; 226(9):2316-28. PubMed ID: 21660955
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, Zhou CC.
    Asian Pac J Cancer Prev; 2012 Sep 01; 13(1):255-60. PubMed ID: 22502680
    [Abstract] [Full Text] [Related]

  • 12. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, Zhang R, Liu X, Zhou S, Wang R, Liu J, Tang X.
    J Cancer Res Clin Oncol; 2020 Jul 01; 146(7):1737-1749. PubMed ID: 32342201
    [Abstract] [Full Text] [Related]

  • 13. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.
    Arch Otolaryngol Head Neck Surg; 2007 Oct 01; 133(10):1022-7. PubMed ID: 17938326
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A, Wiese M.
    ChemMedChem; 2012 Apr 01; 7(4):650-62. PubMed ID: 22354538
    [Abstract] [Full Text] [Related]

  • 15. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y.
    Cancer Sci; 2009 Sep 01; 100(9):1701-7. PubMed ID: 19493273
    [Abstract] [Full Text] [Related]

  • 16. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
    Int J Mol Med; 2007 Jul 01; 20(1):3-10. PubMed ID: 17549382
    [Abstract] [Full Text] [Related]

  • 17. A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.
    Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, Terlecky SR, Boerner JL.
    Exp Cell Res; 2012 Oct 01; 318(16):2014-21. PubMed ID: 22687878
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y.
    Mol Cancer Ther; 2004 Sep 01; 3(9):1119-25. PubMed ID: 15367706
    [Abstract] [Full Text] [Related]

  • 19. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.
    Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V, Stournaras C.
    Cancer Biol Ther; 2009 Aug 01; 8(15):1470-7. PubMed ID: 19483462
    [Abstract] [Full Text] [Related]

  • 20. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
    Cancer Res; 2007 Nov 15; 67(22):11012-20. PubMed ID: 18006847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.